diallyl trisulfide (MedChemExpress)
Structured Review

Diallyl Trisulfide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/diallyl trisulfide/product/MedChemExpress
Average 94 stars, based on 5 article reviews
Images
1) Product Images from "Diallyl Trisulfide Enhances Doxorubicin Chemosensitivity by Inhibiting the Warburg Effect and Inducing Apoptosis in Breast Cancer Cells"
Article Title: Diallyl Trisulfide Enhances Doxorubicin Chemosensitivity by Inhibiting the Warburg Effect and Inducing Apoptosis in Breast Cancer Cells
Journal: Journal of Cancer
doi: 10.7150/jca.113578
Figure Legend Snippet: Diallyl trisulfide demonstrates selective cytotoxicity in normal and cancer cells. (A) Normal cell lines (MCF10, Clone 9, Beas-2B, and AC16) were treated with increasing concentrations of DATS for 24 hours followed by MTT cell viability assay. (B) Cancer cell lines (MCF7, MDA-MB-231, A549, LoVo, and HA22T) were exposed to the same DATS treatment as in (A) , followed by MTT cell viability assay. These results are expressed as a percentage of viable cells from treated groups compared with control. All experiments were conducted in triplicate, ns=not significant, **P < 0.001 and ***P < 0.0001.
Techniques Used: Viability Assay, Control
Figure Legend Snippet: Diallyl trisulfide synergistically enhances doxorubicin cytotoxicity in breast cancer cells. (A and B) Breast cancer cells—(A) MCF7 and (B) MDA-MB-231—were treated with the indicated concentrations of DOX for 24 and 48 hours, followed by MTT cell viability assay. (C and D) Breast cancer cells — (C) MCF7 and (D) MDA-MB-231— were treated with the indicated concentrations of DATS for 24 and 48 hours, followed by the MTT cell viability assay. (E and F) Breast cancer cells— (E) MCF7 and (F) MDA-MB-231—were pre-treated with Dox (0.5 and 1 µM) for 24 hours, followed by the addition of DATS (50 and 100 µM) for a combined treatment period of 48 hours, followed by MTT cell viability assay. (G and H) Combination index (CI) calculation in (G) MCF7 and (H) MDA-MB-231 cells. The CI reflects the degree of drug-drug interactions; in this study, CIs <0.9 indicated synergism, CIs ranging from 0.9 to 1.1 indicated additive effects, and CIs >1.1 indicated antagonistic effects. These results are expressed as a percentage of viable cells from treated groups compared with control cells, ns= not significant, *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Viability Assay, Control
Figure Legend Snippet: Diallyl trisulfide and doxorubicin combination inhibits glucose metabolism in breast cancer cells. (A ) MCF7 and MDA-MB-231 breast cancer cells were treated with DOX (0.5 μM, 1 μM), DATS (50 μM, 100 μM), and their combination, followed by 2-NBDG glucose uptake flow cytometry analysis. (B) The same treatments as in (A) followed by western blot analysis of key glycolytic regulators: GLUT1, PDH, LDHA, and HIF-1α in MCF7 cancer cells. (C) Similar treatment as in A and immunoblotting as in B for MDA-MB-231 cells (D) Similar treatments as in (A) followed by a lactate production colorimetric assay. (E) Lactate production colorimetric assay in MDA-MB-231 cells exposed to LDHA-specific siRNA (50 nM) with or without Doxorubicin (0.5 and 1 µM). (F) Western blot analysis of LDHA, GLUT1 and HIF1α in MDA-MB-231 cells treated with LDHA-siRNA (50 nM) with or without DOX (1 µM). B-Actin is loading control. Data in panels (A), (D), and (E) are expressed as the mean ± SD of treated groups compared to the control, ns=not significant, *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Flow Cytometry, Western Blot, Colorimetric Assay, Control
Figure Legend Snippet: Diallyl trisulfide and doxorubicin combination induces apoptosis in breast cancer cells. (A) MCF7 cancer cells were treated with a combination of DOX (0.5 and 1 μM) and DATS (50 and 100 μM), followed by western blot analysis of the indicated apoptosis markers. (B) MDA-MB-231 cancer cells were treated similarly to (A), followed by western blot analysis. β-Actin was used as the loading control. (C) MCF7 cancer cells were treated similarly to (A), followed by TUNEL staining. (D) MDA-MB-231 cancer cells were treated similarly to (A), followed by TUNEL staining. (E) Annexin V-FITC/PI staining and flow cytometry analysis in MCF7 and MDA-MB-231 cells treated similarly to (A). Data in panels (C), (D), and (E) are expressed as the mean ± SD of treated groups compared to the control, ns=not significant, *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Western Blot, Control, TUNEL Assay, Staining, Flow Cytometry
Figure Legend Snippet: Diallyl trisulfide and doxorubicin combination inhibits MDA-MB-231 breast cancer cell growth in vivo . (A) Combination treatment in vivo experimental design. (B) Monitoring of mouse body weight during the treatment period. (C) Tumor volume monitoring during treatment period. (D) Kaplan-Meier survival analysis from tumor initiation to experiment end point. (E) Bioluminescence imaging of tumor-bearing mice at the end of the experiment. (F) Gross tumor size and weight from each group at the end of the experiment. (G) Western blot analysis of apoptotic markers (BAX, Bcl-xL) and metabolic markers (LDHA) in tumor tissue lysates, B-Actin is loading control. (H) H&E staining (upper panels) and LDHA immunohistochemistry (lower panels) in tumor sections. Representative images are shown, scale bar = 50 nm. Data are expressed as the mean ± SD of treated groups compared to the control, ns=not significant, **P < 0.01, ***P < 0.001.
Techniques Used: In Vivo, Imaging, Western Blot, Control, Staining, Immunohistochemistry

![( A ) The effect of <t>DATS</t> on the viability of MCF-10A cells. MCF-10A cells were treated with 0–100 μM DATS for 24 and 48 h. DATS had no significant effect between 12.5 and 75 μM. Treatment with 100 μM of DATS at 48 h significantly decreased cell viability compared to control. The graph displays all experiments conducted in n = 8 and averaged for three separate experiments. The data were assessed using one-way ANOVA and Dunnett’s multiple comparison test. The average values ± SEM display the results to determine significant differences between the vehicle control and treatments. (* p < 0.05 and ns indicates no significance). ( B ) The effect of B[a]P on viability of MCF-10A cells. MCF-10A cells were treated with 0.01–1 μM B[a]P for 24 and 48 h. Treatment with 1 μM B[a]P and above caused a significant increase in cell viability compared to the control. The graph displays all experiments conducted in n = 8 and averaged for three separate experiments. The data were assessed using one-way ANOVA and Dunnett’s multiple comparison test. The average values ± SEM display the results to determine significant differences between the vehicle control and treatments. (**** p < 0.0001 and ns indicates no significance).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9007/pmc10819007/pmc10819007__nutrients-16-00300-g001a.jpg)
